Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors
CSTR:
Author:
Affiliation:

2.Shenzhen Children's Hospital, Shenzhen, Guangdong 518034, China

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Circulating tumor DNA (ctDNA) is emerging as a novel biomarker for tumor evaluation, offering advantages such as high sensitivity and specificity, minimal invasiveness, and absence of radiation. Currently, various techniques including gene sequencing and PCR are employed for ctDNA detection. The utilization of ctDNA for monitoring minimal residual disease (MRD) enables comprehensive assessment of tumor status and early identification of tumor recurrence, achieving a remarkable detection sensitivity of 0.01%. Therefore, ctDNA holds promise as a biomarker for early diagnosis, treatment response monitoring, and prognosis prediction in solid tumors. This article reviews the commonly used methods for detecting ctDNA and their advantages in evaluating tumor MRD and guiding clinical diagnosis and treatment.

    Reference
    Related
    Cited by
Get Citation

陈颖,文飞球.循环肿瘤DNA作为实体肿瘤微小残留病标志物的研究进展[J].中国当代儿科杂志英文版,2023,(10):1072-1077

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:April 12,2023
  • Revised:
  • Adopted:
  • Online: January 15,2025
  • Published:
Article QR Code